1.The Effects of Alendronate on Healing of the Calvarial Defect in Rats.
Jae Hyung KIM ; Jae Mok LEE ; Jin Woo PARK ; Jo Young SUH
The Journal of the Korean Academy of Periodontology 2004;34(4):733-746
No abstract available.
Alendronate*
;
Animals
;
Diphosphonates
;
Rats*
2.The Effects of Alendronate on healing of the extraction sockets in rats.
Keung Ky MOON ; Jae Mok LEE ; Jo Young SUH
The Journal of the Korean Academy of Periodontology 2001;31(4):713-726
No abstract available.
Alendronate*
;
Animals
;
Rats*
3.Sandwich Trick for Kids and Cells
Journal of Korean Medical Science 2019;34(5):e44-
No abstract available.
Alendronate
;
Cell Proliferation
4.Response: The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Marker in Patients with Osteoporosis (Endocrinol Metab 25:305-309, 2010, Jee-Hoon Koo et al.).
Endocrinology and Metabolism 2011;26(1):108-108
No abstract available.
Alendronate
;
Humans
;
Osteoporosis
;
Vitamin D
;
Vitamins
5.Letter: The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Marker in Patients with Osteoporosis (Endocrinol Metab 25:305-309, 2010, Jee-Hoon Koo et al.).
Endocrinology and Metabolism 2011;26(1):106-107
No abstract available.
Alendronate
;
Humans
;
Osteoporosis
;
Vitamin D
;
Vitamins
6.Effectiveness of alendronate as an adjunct to scaling and root planing in the treatment of periodontitis: a meta-analysis of randomized controlled clinical trials.
Jin CHEN ; Qian CHEN ; Bo HU ; Yunji WANG ; Jinlin SONG
Journal of Periodontal & Implant Science 2016;46(6):382-395
PURPOSE: Alendronate has been proposed as a local and systemic drug treatment used as an adjunct to scaling and root planing (SRP) for the treatment of periodontitis. However, its effectiveness has yet to be conclusively established. The purpose of the present meta-analysis was to assess the effectiveness of SRP with alendronate on periodontitis compared to SRP alone. METHODS: Five electronic databases were used by 2 independent reviewers to identify relevant articles from the earliest records up to September 2016. Randomized controlled trials (RCTs) comparing SRP with alendronate to SRP with placebo in the treatment of periodontitis were included. The outcome measures were changes in bone defect fill, probing depth (PD), and clinical attachment level (CAL) from baseline to 6 months. A fixed-effect or random-effect model was used to pool the extracted data, as appropriate. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Cochrane χ² and I2 tests. RESULTS: After the selection process, 8 articles were included in the meta-analysis. Compared with SRP alone, the adjunctive mean benefits of locally delivered alendronate were 38.25% for bone defect fill increase (95% CI=33.05–43.45; P<0.001; I²=94.0%), 2.29 mm for PD reduction (95% CI=2.07–2.52 mm; P<0.001; I²=0.0%) and 1.92 mm for CAL gain (95% CI=1.55–2.30 mm; P<0.001; I²=66.0%). In addition, systemically administered alendronate with SRP significantly reduced PD by 0.36 mm (95% CI=0.18–0.55 mm; P<0.001; I²=0.0%) and increased CAL by 0.39 mm (95% CI=0.11–0.68 mm; P=0.006; I²=6.0%). CONCLUSIONS: The collective evidence regarding the adjunctive use of alendronate locally and systemically with SRP indicates that the combined treatment can improve the efficacy of non-surgical periodontal therapy on increasing CAL and bone defect fill and reducing PD. However, precautions must be exercised in interpreting these results, and multicenter studies evaluating this specific application should be carried out.
Alendronate*
;
Outcome Assessment (Health Care)
;
Periodontitis*
;
Population Characteristics
;
Root Planing*
7.Alendronate use and Changes in Bone Mineral Density.
Sang Hyup YOON ; Shin Yoon KIM
Journal of the Korean Hip Society 2009;21(1):22-28
PURPOSE: To evaluate the changes in bone mineral density (BMD) after alendronate intake and to determine the side effects and patient compliance. MATERIALS AND METHODS: Two hundred twelve patients with osteoporosis were treated with alendronate. One hundred sixty-two patients were excluded because of early discontinuation. Thus, 50 patients were included in the analysis. RESULTS: The annual increase in BMD in patients taking alendronate was 7.2% (1st year), 3.4%, 2.0%, and 0.9% (4th year) in the L-spine, and 2.2%, 1.5%, -0.9%, and 0.9% in the femur. The changes in BMD of patients< 60 years of age were 2.1% in the L-spine and 3.4% in the femur. The BMD of patients between 60 and 69 years of age increased 6.3% and 0.5% in the L-spine and femur, respectively, and the BMD of patients >70 of age were 2.9% and 1.2% in the L-spine and femur, respectively. The BMD changes in patients with a T-score< -4.0 were 7.0% (L-spine) and 1.2% (femur), the BMD changes in patients with a T-score between -3.0 and -3.9 were 5.3% and 0.2% for the Lspine and femur, respectively, and the BMD changes in patients with a T-score >3.0 were 2.5% and 3.1% for the Lspine and femur, respectively. The reasons for early discontinuation of alendronate were difficulty in intake, economic reasons, and adverse events. CONCLUSION: The BMD changes were greater in the L-spine than the femu in alendronate users. At the first year, the changes in BMD was greatest. There was no significant difference in BMD change according to age. In the Lspine, however, BMD changes were greater in the group with lower T-scores. The early discontinuance rate was 74%, and the adverse events rate was 19.8%.
Alendronate
;
Bone Density
;
Femur
;
Humans
;
Osteoporosis
;
Patient Compliance
8.The Study of Bisphosphonate and Postmenopausal Hormone Treatment in Low Bone Mineral Density
Soo Ah KIM ; Ari KIM ; Yong il JI ; Heung Yeol KIM ; Jong Soon CHOI ; Won Jun CHOI ; Min Hyung JUNG ; Ji Young LEE ; Hyuk JUNG
Journal of Korean Society of Osteoporosis 2011;9(1):132-138
OBJECTIVES: To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women. METHODS: One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment. RESULTS: In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I. CONCLUSIONS: Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.
Absorptiometry, Photon
;
Alendronate
;
Bone Density
;
Female
;
Humans
;
Menopause
;
Spine
9.The Effects of Estrogen Replacement Therapy and Pamidronate on the Bone Metabolism of Postmenopausal Women.
Korean Journal of Obstetrics and Gynecology 2002;45(2):285-291
OBJECTIVE: To evaluate the effects of estrogen replacement therapy and pamidronate on the bone metabolism in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on biochemical markers of bone turnover in 140 women with low bone mass. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus alendronate (group III, n=40) for 12 months. Biochemical markers of bone turnover were also measured at months 6 and 12 months. RESULTS: Serum osteocalcin and urinary deoxypyridinoline in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.05). But total alkaline phosphatase decreased significantly during the treatment in Group III, but not in Group I and Group II. CONCLUSION: The combined treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing bone biochemical markers.
Alendronate
;
Alkaline Phosphatase
;
Biomarkers
;
Estrogen Replacement Therapy*
;
Estrogens*
;
Female
;
Humans
;
Metabolism*
;
Osteocalcin
;
Osteoporosis
;
Postmenopause
;
Prospective Studies
10.Esophageal Ulcer Induced by Alendronate.
Yong Hee JOUNG ; Young Woon CHANG ; Joo Young HAN ; Byoung Wook LEE ; Yo Seb HAN ; Seok Ho DONG ; Hyo Jong KIM ; Byung Ho KIM ; Joung Il LEE ; Rin CHANG
Korean Journal of Gastrointestinal Endoscopy 2004;28(1):25-28
Alendronate sodium (Fosamax(R)) is an aminophosphonate used in treatment of postmenopausal osteoporosis by inhibition of osteoclastic activity. Esophageal ulcers related to alendronate use have been reported at the rate of 2~6%. However, there have been no reports of esophagitis or esophageal ulcer by alendronate in Korea. We present a case of esophageal ulcer caused by alendronate. The patient presented with retrosternal pain and severe odynophagia for a few days. Esophagogastroduodenoscopy revealed multiple deep ulcers at the esophagus. Her symptoms resolved completely after stopping alendronate. A follow-up esophagogastroduodenoscopy 6 weeks later revealed complete healing of the ulcers.
Alendronate*
;
Endoscopy, Digestive System
;
Esophagitis
;
Esophagus
;
Female
;
Follow-Up Studies
;
Humans
;
Korea
;
Osteoclasts
;
Osteoporosis, Postmenopausal
;
Ulcer*